Labopharm’s Painful FDA Experience Continues
This article was originally published in The Pink Sheet Daily
Executive Summary
Canadian firm receives second “approvable” for once-daily analgesic tramadol, may pursue dispute resolution filed in December.
You may also be interested in...
Labopharm Submits Complete Response For Tramadol
Canadian specialty pharma now awaits new action date for delayed once-daily analgesic, already launched in 12 other countries.
Labopharm Submits Complete Response For Tramadol
Canadian specialty pharma now awaits new action date for delayed once-daily analgesic, already launched in 12 other countries.
Labopharm To File Once-Daily Trazodone By Year-End
Firm reports significantly less reawakening at night in pivotal trial of the antidepressant candidate.